Kinnate Biopharma Inc.

Equities

KNTE

US49705R1059

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2024-04-02 pm EDT			5-day change	1st Jan Change
2.65 ^USD	-0.38%		-.--%	+11.81%

Apr. 03	Kinnate Biopharma Inc. Announces Board Resignations	CI
Apr. 03	Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	CI

Kinnate Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 09, 2023 at 04:21 pm EST

Kinnate Biopharma Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 30.73 million compared to USD 30.74 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 0.7 a year ago.
For the nine months, net loss was USD 95.59 million compared to USD 84.71 million a year ago. Basic loss per share from continuing operations was USD 2.06 compared to USD 1.92 a year ago.

Latest news about Kinnate Biopharma Inc.

Kinnate Biopharma Inc. Announces Board Resignations	Apr. 03	CI
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	Apr. 02	CI
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	Apr. 02	CI
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from S&P TMI Index	Apr. 02	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Kinnate Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Kinnate Biopharma Sells Cancer Treatment Assets to Pierre Fabre Laboratories	Mar. 01	MT
Stifel Raises Kinnate Biopharma's Price Target to $2.59 From $1.50, Keeps Hold Rating	Feb. 26	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16	MT
Wedbush Adjusts Kinnate Biopharma's PT to $2.34 From $2 on Heels of Announced Sale Agreement With XOMA, Keeps Neutral Rating	Feb. 16	MT
XOMA Agrees to Acquire Kinnate Biopharma	Feb. 16	MT
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million.	Feb. 15	CI
Kinnate Biopharma Plans to Further Reduce Workforce by 56%	Jan. 17	MT
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	Nov. 15	MT
Top Midday Gainers	Nov. 15	MT
Top Premarket Gainers	Nov. 15	MT
Kinnate Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
North American Morning Briefing : Fed Seen Holding -2-	23-09-20	DJ
Jefferies Cuts Price Target on Kinnate Biopharma to $2 From $31, Maintains Buy Rating	23-09-19	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	23-09-19	MT
Sector Update: Health Care	23-09-19	MT
HC Wainwright Downgrades Kinnate Biopharma to Neutral From Buy	23-09-19	MT
Wedbush Downgrades Kinnate Biopharma to Neutral From Outperform After News of Restructuring, Workforce Reduction; Cuts PT to $2 From $14	23-09-19	MT

Chart Kinnate Biopharma Inc.

Duration

Period

More charts

Company Profile

Kinnate Biopharma Inc. is a clinical-stage precision oncology company. It is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. It is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KINNATE BIOPHARMA INC.	+11.81%	125M
MODERNA, INC.	+12.08%	42.68B
IQVIA HOLDINGS INC.	+0.67%	42.4B
LONZA GROUP AG	+46.45%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B
BIO-TECHNE CORPORATION	-4.80%	11.55B

Other Biotechnology & Medical Research